Strong background in Molecular and Cell Biology and in signal transduction via diverse signaling pathways (GPCR signaling, neurotransmitter receptor signaling, growth factor receptor signaling, kinase/phosphatase-dependent signaling, survival signaling).
Several years of experience in the investigation of disease-associated molecular pathways, especially with those related to neurodegenerative and neuropsychiatric disorders.
Extensive experience in assay development and optimization, including reporter gene assays, ELISA assays and High Throughput Screening assays for drug development.
Extensive experience with automated liquid handling instruments and in the statistical analysis and interpretation of large sets of data for drug screening purposes.
Technical expertise in various cellular, molecular, pharmacological and biochemical techniques and in the culture and genetic engineering of various cell lines and primary neuronal cells.
Excellent experimental design, data analysis and troubleshooting skills Strong publication record with over 1500 citations and several awards. Experience in training/mentoring/supervising junior scientists with different backgrounds and skills.
Experience in writing manuscripts, submitting and revising papers, presenting in scientific conferences, writing grants, reviewing papers for peer-review journals and grants for the Alzheimer's Association.
Several successful collaborations and ability to work under pressure and to maintain highly productive relationships with colleagues and collaborators.
•Alzheimer's Association New Investigator Research Grant Award for the project “PS1 prevents development of Alzheimer's Disease pathological hallmarks via PI3K signaling” (2004).
•The Pine Family Foundation award for research on PS1/PI3K/AKT signaling and Alzheimer's disease (2005).
•World Alzheimer's Congress 2000, Pivotal Research award, (2000).
•NATO/EMBO/FEBS Fellowship for the International Summer School on “Post-transcriptional Control of eukaryotic Gene expression” August 1995-September 1995 Spetses, Greece.
•Developed two assays for prognosis of response to hormonal therapy:
a) Developed a sandwich ELISA assay for quantification of glucocorticoid receptor in human leukemia cells.
b) Developed a reporter gene assay for the responsiveness of cultured human cells to steroids.
A) PEER-REVIEWED ARTICLES
•Baki L., Fribourg M., Younkin J., Eltit J.M., Moreno J.L., Park G., Vysotskaya Z., Narahari A., González-Maeso J., Logothetis D.E. “Cross-signaling in metabotropic Glutamate 2 and serotonin 2A receptor heteromers in mammalian cells” In revision.
•Moreno J.L., Miranda-Azpiazu P., Younkin J., Cui M., Kozlenkov A., Ben-Ezra A., Voloudakis G., Fakira A.K., Baki L., Ge Y., Georgakopoulos A., Morón J.A., Milligan G., López-Giménez J.F., Robakis N.K., Logothetis D.E., Meana J., González-Maeso J. “Mechanistic insights into the allosteric crosstalk between mGlu2 and 5-HT2A receptors acting as an altered heteromer in schizophrenia” Revised and resubmitted.
•Bukiya A.N., Osborn C.V., Kuntamallappanavar G., Toth P.T., Baki L., Kowalsky G., Oh M.J., Dopico A.M., Levitan I., Rosenhouse-Dantsker A. (2015) “Cholesterol increases the open probability of cardiac KACh currents.” Biochim Biophys Acta. 1848(10 Pt A):2406-2413.
•Logothetis D.E., Petrou V.I., Zhang M., Mahajan R., Meng X.Y., Adney S.K., Cui M., Baki L. (2015) “Phosphoinositide Control of Membrane Protein Function: A Frontier Led by Studies on Ion Channels.” Annu Rev Physiol. 77:81-104.
•Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, Park G, Adney SK, Hatcher C, Eltit J-M, Ruta JD, Albizu L, Li Z, Shim J, Fabiato A, MacKerell AD Jr, Brezina V, Sealfon SC, Filizola M, González-Maeso J & Logothetis DE (2011) “Decoding the signaling of a GPCR Heteromeric complex reveals a Unifying mechanism of action of antipsychotic drugs.” Cell. 147(5):1011-23.
•Michailidis IE, Rusinova R, Georgakopoulos A, Chen Y, Iyengar R, Robakis NK, Logothetis DE & Baki L (2011) “Phosphatidylinositol-4,5-bisphosphate Regulates Epidermal Growth Factor Receptor Activation.” Pflugers Arch. 461(3):387-97.
•Deng W, Baki L, Yin J, Zhou H & Baumgarten CM. (2010) “HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.” J Mol Cell Cardiol. 49(5):746-52.
•Deng W, Baki L & Baumgarten CM. (2010) “Endothelin signalling regulates volume-sensitive Cl- current via NADPH oxidase and mitochondrial reactive oxygen species.” Cardiovasc Res. 88(1):93-100.
•Leal-Pinto E, Gómez-Llorente Y, Sundaram S, Tang Q-Y, Ivanova-Nikolova T, Mahajan R, Baki L, Zhang Z, Chavez J, Ubarretxena- Belandia I, & Logothetis DE (2010) “Gating of a G protein-sensitive mammalian Kir3.1 - prokaryotic Kir channel chimera in planar lipid bilayers.” J Biol Chem. 285(51):39790-800.
•Baki L., Neve R., Shao Z., Shioi J., Georgakopoulos A., Robakis N.K. (2008) “Wild-type but not mutant Presenilin-1, prevents neuronal degeneration by promoting neuroprotective phosphatidylinositol 3-kinase signaling.” J Neurosci. 28: 483-490.
•Shioi J., Georgakopoulos A., Pankaj P., Kouchi Z., Claudia M. Litterst CM., Baki L, and Robakis NK (2007) “FAD mutants unable to increase neurotoxic Abeta suggest mutation effects on neurodegeneration may be independent of effects on .” J Neurochem. 101: 674-81.
•Georgakopoulos A, Litterst C, Ghersi E, Baki L, Xu C, Serban G, Robakis NK. (2006) “Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling.” EMBO J. 25(6):1242-52.
•Mitsiou DJ, Florentin I, Baki L, Georgakopoulos A, Alexis MN. (2005) “Pronounced enhancement of glucocorticoid-induced gene expression following severe heat shock of heat-conditioned cells hints to intricate cell survival tactics.” J Steroid Biochem Mol Biol. 94: 209-17.
•Serban G, Kouchi Z, Baki L, Georgakopoulos A, Litterst C.M., Shioi J., and Robakis N.K. (2005) “Cadherins mediate both the association between PS1 and -catenin and the effects of PS1 on -catenin stability.” J. Biol. Chem. 280:36007-12
•Baki L., Shioi J., Wen P., Shao Z., Schwarzman A., Gama-Sosa M., Neve R., Robakis N.K. (2004) “ PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations” EMBO J. 23: 2588-2596.
•Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Baki L, Wen P, Efthimiopoulos S, Shao Z, Wisniewski T, Robakis NK. (2002). “A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions.” EMBO J. 21(8):1948-56.
•Baki L, Marambaud P, Efthimiopoulos S, Georgakopoulos A, Wen P, Cui W, Shioi J, Koo E, Ozawa M, Friedrich VL, and Robakis NK (2001) “Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of the cadherin/catenin adhesion complex.” Proc Natl Acad Sci U S A ;98:2381-2386.
•Baki, L. and Alexis, M.N. (1996) “Regulation of tyrosine aminotransferase gene expression by glucocorticoids in quiescent and regenerating liver” Biochem. J. 320, 745-753.
•Baki, L. and Alexis, M.N. (1994) “The efficiency of nuclear processing of the tyrosine aminotransferase transcript increases after partial hepatectomy.” Eur. J. Biochem./FEBS 225, 797-803.
•Alexis, M.N., Baki, L., Elefteriou, C. and Sekeris, C.E. (1988) “Glucocorticoid receptor structure as probed by endogenous proteases.” J. Steroid Biochem. 30, 225-231.
•Alexis M.N., Mavridou I., Baki L. and Kioussi C. (1987). “The receptor for glucocorticoid hormones; an insight into its structure and cellular dynamics.” Klinical Pharmacol. Pharmakokin. 1, 39-54.
B) BOOK CHAPTERS
•Baki L., and Robakis N.K. (2005) “A gamma-secretase independent function of PS1 links cell-cell adhesion to Alzheimer's Disease pathology; effects of PS1 FAD mutations.” New Trends in Alzheimer and Parkinson related Disorders, MEDIMOND International Proceedings ADPD 2005, F309C0404, 41-45.
•Baki L., Shioi J., and Robakis N.K. (2004) “PS1 FAD mutations promote tau over-phosphorylation and apoptosis by causing a loss of PS1 function in cadherin/PI3K/Akt/GSK-3 signaling.” Research Advances in Alzheimer's Disease and Related Disorders (Iqbal, K. and Winblad, B. eds.): 142-149.
•Marambaud, P., Georgakopoulos, A., Baki L., Shioi, j. and Robakis, N. K. (2003) “Presenilin-1 regulates Processing, Signaling and Function of the Cadherin family of Proteins: Implications for Alzheimer's Disease.” In: Alzheimer's Disease and Related Disorders: Research Advances. (Iqbal, K. and Winblad, B. eds.) Ana Aslan, pp. 407-414.
•Georgakopoulos, A., Marambaud, P., Robakis, NK., Baki, L. (2001) “Presenilin-1 is a regulatory component of the cadherin cell adhesion complex: Implications for Alzheimer's disease.” in “Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics” John Wiley & Sons, Ltd., Chichester, UK, 2001.
C) MOST RELEVANT CONFERENCE PAPERS (out of 18; full list available upon request)
•L Baki, J Younkin, JM Eltit, M Fribourg, G Park, Z Vysotskaya, DE Logothetis (2015) “Cross-Signaling between the Metabotropic Glutamate 2 Receptor and the Serotonin 2A Receptor in HEK-293 Cells.” Biophysical Journal 108(2) pp. 416a.
•J Younkin, L Baki, A Ellaithy, DE Logothetis (2015) “Allosteric Effects of G-Protein Coupled Receptor Heteromerization: Relevance to Psychosis.” Biophysical Journal 108(2) pp. 95a.
•A Ellaithy, J Younkin, L Baki, DE Logothetis (2015) “A Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor Alters 5-HT2A Receptor Signaling in a Heteromeric Complex.” Biophysical Journal 108(2) pp. 416a
•L Baki, JM Eltit, M Fribourg, J Younkin, G Park, Z Vysotskaya, SC Sealfon, G Liapakis, J Gonzalez-Maeso, DE Logothetis (2013) “Functional Crosstalk between mGluR2 and 5-HT2A Depends on their Expression Ratios.” Biophysical Journal104(2) pp. 116a.
•L Baki, RL Neve, Z Shao, J Shioi, A Georgakopoulos, NK Robakis “Presenilin1 prevents neurodegeneration by stimulating PI3K/Akt neuroprotective signaling: Effects of PS1 familial Alzheimer's disease mutations.” Alzheimer's and Dementia , Volume 4, Issue 4, Supplement 1, July 2008, Page T728.
•NK Robakis, L Baki “Presenilin FAD mutants promote neurodegeneration and AD pathology by inhibiting the presenilin function in PI3K/Akt signaling.” Alzheimer's and Dementia, Volume 2, Issue 3, Supplement 1, July 2006, Page S496.
•L Baki, J Shioi, P Wen, Z Shao, M Gama-Sosa, A Schwarzman, R Neve, NK Robakis “PS1 suppresses apoptosis and prevents Tau hyperphosphorylation via cadherin/PI3K signaling; effects of PS1 FAD mutations.” Neurobiology of Aging, Volume 25, Sup 2, July 2004, Page S562.
•J Shioi, L Baki, P Wen, Z Shao, P Davies, NK Robakis “Role of presenilin 1 and its FAD mutations in the cadherin/PI3K/AKT pathway investigated in animal models.” Neurobiology of Aging, Volume 25, Sup 2, July 2004, Page S566.
•L Baki, P Marambaud, S Efthimiopoulos, P Wen, T Georgakopoulos, NK Robakis “PS1 is a regulatory component of the cadherin/catenin adherens junction system.” Neurobiology of Aging, Volume 21, Sup 1, May-June 2000, Page 68.
•P Marambaud, L Baki, A Georgakopoulos, J Shioi, S Efthimiopoulos, M Ozawa, NK Robakis “Molecular organization of presenilin 1 in the E-cadherin/catenins cell adhesion system.” Neurobiology of Aging, Volume 21, Sup 1, May-June 2000, Page 181.
Six invited presentations and 14 first author presentations in International Conferences (list available upon request).
TRAINING / MENTORING / SUPERVISING EXPERIENCE
2008-present:One technician, two Masters Students, two PhD students, one summer student.
2003 - 2008: One technician, one PhD student, one rotation student, three postdoctoral fellows.
1998 to 2002: One technician and two summer students.
REVIEWER EXPERIENCE AND PROFESSIONAL AFFILIATIONS
•Reviewer for grant proposals submitted to the Alzheimer's Association and for articles submitted to several journals.
•Member of the Biophysical Society, the Society of Neuroscience, and the Alzheimer's Research Forum.
•Cell culture-related techniques: Culture of primary neuronal cells and various immortalized cell lines, transient and stable transfection, gene delivery with viral vectors, monitoring of in vivo responses to various inhibitors and activators.
•Molecular biology techniques: Sub-cloning, PCR, site-directed mutagenesis, isolation and purification of RNA and genomic DNA, in vitro transcription of mRNA, siRNA, RT-PCR.
•Biochemical techniques: Western Blotting, immunoprecipitation, cross-linking, immunocytochemistry, in vitro kinase assays, ELISA.
•Cell biology techniques: Cell cycle, cell viability and apoptosis assays (3H-thymidine incorporation, DAPI/ flow cytometry, TUNNEL assay, DNA fragmentation assay, Annexin staining, Caspase activity), cell migration and cell aggregation assays, metabolic assays (ATP production assay, MTT assay, fluorescence based assays for mitochondria integrity).
•Biophysical techniques: Calcium Imaging (FLUO-4, FURA-2) and use of fluorescent potentiometric probes (DiBAC4(3), HLB-O21, FLIRP) in high throughput assays, using automated liquid handling instruments (FlexStation).
•Microscopy: Phase contrast, fluorescence, confocal.
•Experimental animals: Generation of transgenic mice, breeding, maintenance and use of genetically engineered in vivo models of neurodegeneration (knockout mice, transgenic mice).
Resumes, and other information uploaded or provided by the user, are considered User Content governed by our Terms & Conditions. As such, it is not owned by us, and it is the user who retains ownership over such content.
Companies Worked For:
Job Titles Held: